You are here: Industry Insights > SCYNEXIS

News List

SCYNEXIS Announces Positive Results of Oral Ibrexafungerp to Treat Severe Fungal Infections americanpharmaceuticalreview
March 05, 2021
SCYNEXIS announced positive results from the third interim efficacy analysis of the ongoing open-label Phase 3 FURI study and the first interim analysis of the ongoing open-label Phase 3 CARES study.
SCYNEXIS Announces Positive Results from Ibrexafungerp Study americanpharmaceuticalreview
January 13, 2020
SCYNEXIS announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study. The study is evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and ...
SCYNEXIS Completes Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp americanpharmaceuticalreview
May 31, 2019
SCYNEXIS announced the company has completed the nonclinical toxicology evaluations that are required by regulatory authorities, including the U.S. Food and Drug Administration (FDA), to support long-term administration in human clinical trials.